A news item in the July 11, 2001, issue of BioWorld Today incorrectly stated that Introgen Therapeutics Inc.s INGN 201 is in Phase II studies in head and neck cancer. The product is in Phase III pivotal trials in that indication.
Editors Note: The correction has been made in BioWorld Online.